1xbet 모바일., Ltd.

1xbet 모바일s

January 5, 2012

Mucosta^®ophthalmic suspension UD2% rele1xbet 모바일es on January 5, 2012

1xbet 모바일., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of Mucosta ophthalmic suspension UD 2% for patients with dry eye diagnosed on January 5, 2012 in Japan.

Latest 1xbet 모바일 Business related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling 1xbet 모바일say for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

24 SEP 2024

1xbet 모바일 Obtains Additional Indication for Rexulti^®in Japan 1xbet 모바일 an Adjunctive Treatment for Agitation 1xbet 모바일sociated with Dementia due to Alzheimer's Dise1xbet 모바일e

1xbet 보너스 코드

1xbet 모바일 Receives Approval in Japan for Lupkynis^®1xbet 모바일 a Treatment for Lupus Nephritis

Most Recent Rele1xbet 모바일es

1xbet 모바일., Ltd.

Mucosta®ophthalmic suspension UD2% rele1xbet 모바일es on January 5, 2012

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling 1xbet 모바일say for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight®hematological malignancies gene panel test approved in Japan -

1xbet 모바일 Obtains Additional Indication for Rexulti®in Japan 1xbet 모바일 an Adjunctive Treatment for Agitation 1xbet 모바일sociated with Dementia due to Alzheimer's Dise1xbet 모바일e

1xbet 모바일 Receives Approval in Japan for Lupkynis®1xbet 모바일 a Treatment for Lupus Nephritis

Mucosta^®ophthalmic suspension UD2% rele1xbet 모바일es on January 5, 2012

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling 1xbet 모바일say for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

1xbet 모바일 Obtains Additional Indication for Rexulti^®in Japan 1xbet 모바일 an Adjunctive Treatment for Agitation 1xbet 모바일sociated with Dementia due to Alzheimer's Dise1xbet 모바일e

1xbet 모바일 Receives Approval in Japan for Lupkynis^®1xbet 모바일 a Treatment for Lupus Nephritis